Income Statement Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186.14 CHF | +0.96% |
|
+2.54% | - |
| 07-20 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… | |
| 07-13 | BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | |||||
Total Revenues | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | |||||
Cost of Goods Sold, Total | 2.2B | 2.51B | 2.6B | 2.64B | 2.61B | |||||
Gross Profit | 1.34B | 1.46B | 1.53B | 1.41B | 1.4B | |||||
Selling General & Admin Expenses, Total | 578M | 658M | 736M | 724M | 728M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 125M | 147M | 137M | 138M | 179M | |||||
Other Operating Expenses, Total | 703M | 804M | 873M | 862M | 907M | |||||
Operating Income | 634M | 659M | 656M | 546M | 498M | |||||
Interest Expense, Total | -73.91M | -59.29M | -137M | -126M | -107M | |||||
Interest And Investment Income | 652K | 780K | 5.2M | 8.58M | 4.94M | |||||
Net Interest Expenses | -73.26M | -58.51M | -132M | -118M | -102M | |||||
Income (Loss) On Equity Invest. | -30.42M | -26.78M | 97.83M | -12.91M | -24.91M | |||||
Currency Exchange Gains (Loss) | -31.8M | -46.53M | - | - | - | |||||
Other Non Operating Income (Expenses) | 5.06M | -18.4M | -96.68M | 2.02M | 3.35M | |||||
EBT, Excl. Unusual Items | 504M | 508M | 526M | 417M | 374M | |||||
Restructuring Charges | -6.86M | - | -29.68M | -107M | -99.81M | |||||
Merger & Related Restructuring Charges | -39.1M | -8.74M | -12.38M | -1.5M | -1.2M | |||||
Impairment of Goodwill | - | - | - | -215M | -165M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 22.7M | 123M | -961K | -659K | 3.38M | |||||
Asset Writedown | - | - | - | - | -211M | |||||
Other Unusual Items | - | - | 98.5M | - | - | |||||
EBT, Incl. Unusual Items | 481M | 623M | 581M | 93.11M | -99.5M | |||||
Income Tax Expense | 81.87M | 130M | 101M | 67.82M | 42.66M | |||||
Earnings From Continuing Operations | 399M | 493M | 480M | 25.29M | -142M | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 399M | 493M | 480M | 25.29M | -142M | |||||
Minority Interest | -7.86M | -6.38M | -5.75M | -3.09M | -2.18M | |||||
Net Income - (IS) | 391M | 486M | 475M | 22.2M | -144M | |||||
Preferred Dividend and Other Adjustments | - | - | - | 11.91M | - | |||||
Net Income to Common Incl Extra Items | 391M | 486M | 475M | 10.3M | -144M | |||||
Net Income to Common Excl. Extra Items | 391M | 486M | 475M | 10.3M | -144M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 7.77 | 9.57 | 9.27 | 0.2 | -2.91 | |||||
Basic EPS - Continuing Operations | 7.77 | 9.57 | 9.27 | 0.2 | -2.91 | |||||
Basic Weighted Average Shares Outstanding | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M | |||||
Net EPS - Diluted | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | |||||
Diluted EPS - Continuing Operations | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | |||||
Diluted Weighted Average Shares Outstanding | 51.42M | 51.3M | 51.45M | 51.63M | 49.56M | |||||
Normalized Basic EPS | 6.11 | 6.13 | 6.3 | 5.02 | 4.67 | |||||
Normalized Diluted EPS | 5.97 | 6.07 | 6.28 | 4.99 | 4.67 | |||||
Supplemental Items | ||||||||||
EBITDA | 900M | 962M | 970M | 870M | 877M | |||||
EBITA | 759M | 805M | 794M | 675M | 677M | |||||
EBIT | 634M | 659M | 656M | 546M | 498M | |||||
EBITDAR | 951M | 1.04B | 1.06B | 972M | 986M | |||||
Total Revenues (As Reported) | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | |||||
Effective Tax Rate - (Ratio) | 17.03 | 20.93 | 17.36 | 72.84 | -42.87 | |||||
Current Domestic Taxes | 41.98M | 94.84M | 66.91M | 48.52M | 20.6M | |||||
Current Foreign Taxes | 60.2M | 68.64M | 85.36M | 86.49M | 97.43M | |||||
Total Current Taxes | 102M | 163M | 152M | 135M | 118M | |||||
Deferred Domestic Taxes | -34.2M | -31.97M | -52.13M | -60.27M | -52.95M | |||||
Deferred Foreign Taxes | 13.89M | -1.13M | 779K | -6.92M | -22.42M | |||||
Total Deferred Taxes | -20.31M | -33.11M | -51.35M | -67.19M | -75.37M | |||||
Normalized Net Income | 307M | 311M | 323M | 258M | 232M | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | 1.28M | 1.44M | 1.48M | 1.55M | 1.39M | |||||
Non-Cash Pension Expense | -889K | 2.16M | 3.15M | 4.98M | 4.39M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | - | |||||
Net Rental Expense, Total | 50.78M | 74.68M | 89.05M | 102M | 109M | |||||
Imputed Operating Lease Interest Expense | 11.75M | 11.61M | 31.04M | 34.88M | 34.63M | |||||
Imputed Operating Lease Depreciation | 39.04M | 63.06M | 58.02M | 67.11M | 74.82M | |||||
Stock-Based Comp., COGS (Total) | 13.09M | 14.85M | 15.05M | 15.66M | 16.72M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 58.39M | 58.76M | 57M | 54.23M | 54.37M | |||||
Total Stock-Based Compensation | 71.47M | 73.62M | 72.05M | 69.89M | 71.08M |
Select your edition
All financial news and data tailored to specific country editions
















